What are the medical insurance reimbursement conditions for lenvatinib/lenvatinib and how to apply?

Lenvatinib is an oral small molecule multi-target tyrosine kinase inhibitor (TKI) that exerts anti-tumor effects at the molecular level by inhibiting multiple signaling pathways related to tumor angiogenesis and cell proliferation, such as VEGFR, FGFR, PDGFR, RET and KIT. Its broad-spectrum target characteristics enable lenvatinib to demonstrate clinical potential in the treatment of multiple solid tumors, and it has been approved by multiple national drug regulatory agencies for the treatment of specific types of cancer.

In China, lenvatinib has been approved for the treatment of unresectable liver cancer (HCC), advanced differentiated thyroid cancer (DTC) and advanced renal cell carcinoma (RCC). Especially for the indication of liver cancer, lenvatinib has been highly recognized by the National Medical Products Administration (NMPA) for its efficacy and safety. With the accumulation of clinical research data, its combination immunotherapy regimen (such as combination with pembrolizumab) is also being continuously verified in multiple clinical trials around the world. It is worth noting that as an oral targeted drug, lenvatinib treatment requires long-term persistence, so the cost issue is also a common concern of patients.

Regarding medical insurance, lenvatinib has been included in China’s National Medical Insurance Drug List. In the currently announced medical insurance policy, all patients diagnosed with advanced hepatocellular carcinoma or progressive differentiated thyroid cancer who meet the medication standards can enjoy medical insurance reimbursement. The reimbursement ratio and specific threshold of medical insurance need to be determined according to the medical insurance policy of the patient's location, and there may be slight differences in different regions.

To sum up, lenvatinib, as a targeted drug that has entered the Chinese market and been included in medical insurance, provides patients with more precise treatment options for multiple indications such as liver cancer and thyroid cancer.

Reference materials:https://www.lenvima.com/